• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·LASA.NS
Share

Lasa Supergenerics Limited Stocks

₹ 4.91Last Updated 19.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

₹ 2.72M

₹ 4.91
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Lasa Supergenerics Limited, founded in 2016 and based in Mumbai, India, specializes in the development, manufacturing, and commercialization of various healthcare products for both human and animal well-being. Its operations predominantly cater to the Indian domestic market, though the firm also distributes its offerings internationally. The company's product portfolio includes active pharmaceutical ingredients (APIs) for veterinary applications and other uses, as well as anthelmintic drugs, ingredients for animal feed, and specialized reagents employed in therapeutic treatments.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

22.10.2026 17:05

Investors seeking safe havens have driven the valuations of "toothpaste" stocks above those of the tech sector

22.10.2026 16:35

Dividends, Gold, ETFs: Wall Street Outlines 5 Steps to Protect Your Portfolio from AI Risks

22.10.2026 16:35

Nebius Secured a $3.5 Billion Credit Line Amid a Sell-Off in AI-Sector Stocks

22.10.2026 15:47

AI Needs Energy and Power: 3 Stocks from Griffin's Portfolio with Growth Potential of Up to 400%

22.10.2026 15:25

Morning in New York: Tech Giants Wake Up the "Bears"

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026